Catálogo de publicaciones - libros
Cardiac Drug Therapy
M. Gabriel Khan
Seventh Edition.
Resumen/Descripción – provisto por la editorial
No disponible.
Palabras clave – provistas por la editorial
Cardiology; Internal Medicine; General Practice / Family Medicine; Pharmacology/Toxicology
Disponibilidad
Institución detectada | Año de publicación | Navegá | Descargá | Solicitá |
---|---|---|---|---|
No detectada | 2007 | SpringerLink |
Información
Tipo de recurso:
libros
ISBN impreso
978-1-58829-904-8
ISBN electrónico
978-1-59745-238-0
Editor responsable
Springer Nature
País de edición
Reino Unido
Fecha de publicación
2007
Información sobre derechos de publicación
© Humana Press Inc. 2007
Cobertura temática
Tabla de contenidos
Management of Acute Myocardial Infarction
M. Gabriel Khan
Acute coronary syndrome (ACS) embraces ST-segment-elevation myocardial infarction (STEMI) and non-ST-elevation MI (NSTEMI)-ACS (). The terms Q-wave and non-Q-wave MI are no longer used. Patients presenting with NSTEMIACS symptoms without biochemical markers of acute myocardial infarction (AMI) (particularly elevated troponin) are regarded as having unstable angina (Fig. 11).
Pp. 183-210
Management of Heart Failure
M. Gabriel Khan
Heart failure (HF), unlike coronary heart disease (CHD), has no territorial boundaries.
Pp. 211-240
Heart Failure Controversies
M. Gabriel Khan
The prevalence of heart failure (HF) rises from 2% to 3% at age 65 to more than 50% in persons older than age 80. Many of these patients have HFPEF. The condition is not uncommon in elderly women, most of whom have hypertension, diabetes mellitus, or both and often coronary heart disease (CHD). However, CHD more commonly causes systolic heart failure (SHF). Atrial fibrillation is common in the elderly, and ventricular rates even when not very rapid (120-140) may precipitate HF with a preserved ejection fraction (EF).
Pp. 241-248
Management of Cardiac Arrhythmias
M. Gabriel Khan
The rational basis of antiarrhythmic therapy ideally requires a knowledge of
Pp. 249-283
Cardiac Arrest
M. Gabriel Khan
Approximately a quarter million individuals die suddenly from cardiac arrest (C A) in the United States each year before they reach a hospital (). It is relevant that approx 50% of patients with ventricular fibrillation (VF) survive cardiopulmonary resuscitation (CPR) versus amplt;10% for other rhythms, represented by asystole and pulseless electrical activity (PEA). The incidence of VF in most surveys of C A is approx 50%. Thus immediate defibrillation remains the mainstay of therapy for C A, and this concept is endorsed by the American Heart Association (AHA) 2005 guidelines (–).
Pp. 285-295
Management of Infective Endocarditis
M. Gabriel Khan
Infective endocarditis (IE) most often results from bacterial infection, but infections caused by fungi, , or are not rare. Infection usually involves heart valves not always previously known to be abnormal, in particular a bicuspid aortic valve, mitral valve prolapse, or (rarely) a septal defect or ventricular aneurysm. Coarctation of the aorta, patent ductus arteriosus, aneurysms, or arteriovenous shunts may be the site of infective endarteritis. Prosthetic valves may be involved, and infection at the site of implantation of foreign material including devices poses a particularly difficult problem.
Pp. 297-306
Management of Dyslipidemias
M. Gabriel Khan
This chapter covers the following areas:
Pp. 307-322
Statin Controversies
M. Gabriel Khan
A Study to Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived Coronary atheroma burden (ASTEROID) trial showed that very-high-intensity statin therapy resulted in significant regression of atherosclerosis for all three prespecified measures of disease burden ().
Pp. 323-329
Antiplatelet Agents, Anticoagulants, and Specific Thrombin Inhibitors
M. Gabriel Khan
Antiplatelet agents are used in virtually all patients with coronary heart disease (CHD). Aspirin, the pioneer hallmark agent, is of proven value for the management of
Pp. 331-348
Cardiac Drugs During Pregnancy and Lactation
M. Gabriel Khan
Most cardiovascular agents (like all other drugs) must be avoided in the first trimester of pregnancy because they may produce congenital malformations, especially from the 3rd to the 1 lth week of pregnancy.
Pp. 349-361